[PR Newswire] - WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment